Patient Death Taints Otherwise Positive Data for Beam’s Sickle Cell Gene Therapy

BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, but a patient death underscores the need for less-toxic preconditioning treatments.